Study ID: Actuate 1801


Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

A study to investigate 9-ING-41 alone, or in combination with various standard of care treatment options for adult patients (18 years or older) with advanced cancers where: the cancer has stopped responding to previous treatment; the cancer has come back after previous treatments, or other standard treatments are not suitable for the patient due to side effects or a low chance of benefit.
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
HEME (Hematologic), Solid Tumors, Bones and Joints, Brain and Nervous System, Breast - Invasive, CNS (Brain Tumors), Colorectal, Gynecologic, Other, Hodgkins Lymphoma, Lung, NBL (Neuroblastoma), NHL (Non-Hodgkins Lymphoma), Pancreas, REN (Renal)
Phase I/II
Active - Open to Accrual